We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 355

Science publisher claims submission of prior art to USPTO involves copyright infringement
  • Shook Hardy & Bacon LLP
  • USA
  • March 15 2012

A New Jersey-based publishing company has filed copyright infringement lawsuits in federal courts in two states against law firms that submitted citations to or copies of copyrighted articles from scientific journals to the U.S. Patent and Trademark Office (USPTO) with their clients’ patent applications


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Australia, Canada, European Union, United Kingdom, USA
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


Pharma trade group seeks biologics data exclusivity for international trade
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

PhRMA has reportedly called for the U.S. Trade Representative to go outside provisions in the Korea-U.S. trade deal (KORUS) and press for a 12-year period of exclusivity for biologics in ongoing Trans-Pacific Partnerships (TPP) negotiations


Medicinova and Zhejiang Medicine announce joint venture in China
  • Shook Hardy & Bacon LLP
  • China, USA
  • March 10 2011

California-based biopharmaceutical company MediciNova Inc. and Zhejiang Medicine Co., a Chinese pharmaceutical manufacturer, have announced a joint venture to develop and commercialize MediciNova’s MN-221 in China


Takeda acquires access to Envoy’s CNS drug pipeline and bacTRAP technology
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

Takeda America Holdings, Inc. has reportedly acquired Envoy Therapeutics, Inc. in a deal worth $140 million, including an up-front payment and progressdependent milestone payments


Presidential bioethics panel to examine genome privacy
  • Shook Hardy & Bacon LLP
  • USA
  • April 19 2012

The Presidential Commission for the Study of Bioethical Issues is seeking public comments “on the ethical issues raised by the ready availability of large-scale human genome sequence data, with regard to privacy and data access and the balancing of individual and societal interests.”


FDA issues industry guidance on off-label information about drugs, medical devices
  • Shook Hardy & Bacon LLP
  • USA
  • January 19 2012

The Food and Drug Administration (FDA) has issued draft guidance on how the pharmaceutical and medical device industry should respond to unsolicited requests for off-label information about their FDA-approved prescription drugs and medical devices


FDA targets “high-risk” compounding pharmacies for inspection
  • Shook Hardy & Bacon LLP
  • USA
  • March 7 2013

The Food and Drug Administration (FDA) has reportedly begun focusing its investigative efforts on compounding pharmacies at "high risk" for


Pharmacy and hospital interests present comments on proposed compounding bill
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Proposed legislation (S. 959) that would give the U.S. Food and Drug Administration (FDA) the authority to oversee compounding pharmacies that ship


IOM publishes report on the effects of falsified and substandard medicines
  • Shook Hardy & Bacon LLP
  • Global, USA
  • February 21 2013

At the request of the U.S. Food and Drug Administration (FDA), national think tank the Institute of Medicine (IOM) has published a report that